Zinger Key Points
- Enveric’s EB-003 shows promising safety data, targeting serotonin receptors without inducing hallucinations.
- The company plans to file an Investigational New Drug application by Q3 2025, with clinical development starting by year-end.
- The ‘Trade of the Day’ is now live. Get a high-probability setup with clear entry and exit points right here.
Enveric Biosciences ENVB, a biotechnology company specializing in neuroplastogenic small-molecule therapeutics, revealed positive data from preclinical safety and pharmacology studies of its lead drug candidate, EB-003. The Massachusetts-based company announced that the results show the drug's ability to selectively target serotonergic receptors, offering potential benefits for mental health conditions such as depression, anxiety and addiction without inducing hallucinations.
What Happened: The in vitro studies demonstrated EB-003’s selective activity on serotonergic neuroreceptors while confirming its minimal off-target interactions. These findings reduce concerns about the adverse cardiovascular and central nervous system (CNS) events commonly associated with serotonin-like compounds.
Why It Matters: The studies, which examined EB-003's effects on a broad spectrum of biological targets, revealed that the compound did not show significant interaction with critical cardiovascular or CNS receptors. In particular, EB-003 showed no interaction with the hERG potassium channel or the serotonin receptor 5-HT2B, both of which are associated with severe cardiovascular risks such as pulmonary hypertension and valvular heart disease.
“From our perspective, positive results from this key in vitro safety screen further de-risk EB-003,” said Dr. Joseph Tucker, director and CEO of Enveric. “These results, along with previously reported antidepressant, anxiolytic and neuroplastogenic properties in animal models, enhance our confidence in this lead compound.”
The study also noted EB-003’s lack of activity on the M1 muscarinic acetylcholine receptor, a target known to influence cognition and perception, reducing the risk of CNS-related adverse reactions such as drug-induced delirium.
What’s Next: Following these encouraging preclinical results, Enveric plans to advance EB-003 into in vivo toxicology and safety pharmacology activities in the fourth quarter of 2024. The company anticipates filing an Investigational New Drug application by the third quarter of 2025, with clinical development set to begin by the year's end.
Cover image made with AI
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!